REPLIGEN CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that REPLIGEN CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $41.61M | Feb 22, 2018 |
| FY2017 | Sep 30, 2017 | $36.58M | Feb 22, 2018 |
| FY2017 | Jun 30, 2017 | $32.46M | Feb 22, 2018 |
| FY2017 | Mar 31, 2017 | $30.59M | Feb 22, 2018 |
| FY2017 | Dec 31, 2016 | $25.60M | Feb 22, 2018 |
| FY2017 | Sep 30, 2016 | $24.68M | Feb 22, 2018 |
| FY2017 | Jun 30, 2016 | $29.17M | Feb 22, 2018 |
| FY2017 | Mar 31, 2016 | $25.09M | Feb 22, 2018 |
| FY2016 | Dec 31, 2015 | $21.45M | Feb 23, 2017 |
| FY2016 | Sep 30, 2015 | $19.81M | Feb 23, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $60.49M | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | $54.43M | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | $50.60M | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | $44.11M | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | $39.35M | Feb 24, 2021 |
| FY2020 | Sep 30, 2019 | $38.02M | Feb 24, 2021 |
| FY2020 | Jun 30, 2019 | $39.98M | Feb 24, 2021 |
| FY2020 | Mar 31, 2019 | $33.79M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $28.35M | Feb 26, 2020 |
| FY2019 | Sep 30, 2018 | $27.35M | Feb 26, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $48.89M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($25.51M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $35.60M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $185.96M | Mar 14, 2025 |
| FY2023 | Dec 31, 2021 | $128.29M | Nov 18, 2024 |
| FY2020 | Dec 31, 2020 | $19.70M | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | $14.55M | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | $15.86M | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | $9.82M | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | $3.60M | Feb 24, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $55.17M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($35.11M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $47.70M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $224.67M | Mar 14, 2025 |
| FY2023 | Dec 31, 2021 | $167.25M | Nov 18, 2024 |
| FY2022 | Dec 31, 2020 | $69.82M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $36.08M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $25.99M | Feb 24, 2021 |
| FY2017 | Dec 31, 2017 | $3.26M | Feb 22, 2018 |
| FY2017 | Sep 30, 2017 | ($406.0K) | Feb 22, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $54.18M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $43.20M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $42.72M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $43.94M | Mar 14, 2025 |
| FY2023 | Dec 31, 2021 | $34.27M | Nov 18, 2024 |
| FY2022 | Dec 31, 2020 | $20.18M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $19.45M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $15.82M | Feb 24, 2021 |
| FY2017 | Dec 31, 2017 | $3.07M | Feb 22, 2018 |
| FY2017 | Sep 30, 2017 | $2.00M | Feb 22, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $290.51M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $263.37M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $218.58M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $215.83M | Mar 14, 2025 |
| FY2023 | Dec 31, 2021 | $183.87M | Nov 18, 2024 |
| FY2022 | Dec 31, 2020 | $119.62M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $95.61M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $65.69M | Feb 24, 2021 |
| FY2017 | Dec 31, 2017 | $16.14M | Feb 22, 2018 |
| FY2017 | Sep 30, 2017 | $15.00M | Feb 22, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $117.42M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $175.39M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $113.92M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $172.08M | Mar 14, 2025 |
| FY2023 | Dec 31, 2021 | $119.02M | Nov 18, 2024 |
| FY2022 | Dec 31, 2020 | $62.63M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $67.22M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $32.77M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $17.45M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $7.52M | Mar 1, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $23.52M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $25.68M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $36.22M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $84.83M | Mar 14, 2025 |
| FY2023 | Dec 31, 2021 | $67.09M | Nov 18, 2024 |
| FY2022 | Dec 31, 2020 | $22.46M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $18.50M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $10.64M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $5.45M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $4.33M | Mar 1, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.95B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $2.83B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $2.83B | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $2.53B | Nov 18, 2024 |
| FY2022 | Dec 31, 2021 | $2.36B | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $1.90B | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $1.40B | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $774.62M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $743.52M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $288.91M | Feb 22, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $843.57M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $856.95M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $866.34M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $620.90M | Nov 18, 2024 |
| FY2022 | Dec 31, 2021 | $608.29M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $373.74M | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $340.35M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $159.05M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $151.97M | Mar 1, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.11B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.97B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $1.96B | Feb 26, 2026 |
| FY2025 | Dec 31, 2022 | $1.91B | Feb 26, 2026 |
| FY2024 | Dec 31, 2021 | $1.75B | Mar 14, 2025 |
| FY2023 | Dec 31, 2020 | $1.53B | Nov 18, 2024 |
| FY2022 | Dec 31, 2019 | $1.06B | Feb 22, 2023 |
| FY2021 | Dec 31, 2018 | $615.57M | Feb 17, 2022 |
| FY2020 | Dec 31, 2017 | $591.55M | Feb 24, 2021 |
| FY2019 | Dec 31, 2016 | $168.76M | Feb 26, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.11B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.03B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $987.12M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $855.51M | Mar 14, 2025 |
| FY2023 | Dec 31, 2021 | $860.36M | Nov 18, 2024 |
| FY2022 | Dec 31, 2020 | $618.31M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $468.41M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $326.74M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $327.33M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $59.55M | Mar 1, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $456.25M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $407.35M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $432.87M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $397.27M | Nov 18, 2024 |
| FY2022 | Jan 1, 2022 | $17.30M | Feb 22, 2023 |
| FY2022 | Dec 31, 2021 | $194.06M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $65.77M | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $5.84M | Feb 24, 2021 |
| FY2020 | Dec 31, 2018 | ($677.0K) | Feb 24, 2021 |
| FY2018 | Dec 31, 2017 | ($31.51M) | Mar 1, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $566.02M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $757.36M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $751.32M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $523.46M | Nov 18, 2024 |
| FY2022 | Dec 31, 2021 | $603.81M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $717.29M | Feb 17, 2022 |
| FY2021 | Dec 31, 2019 | $528.39M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $193.82M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $173.76M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $122.23M | Mar 1, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $542.21M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $525.57M | Feb 26, 2026 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 3 | Mar 14, 2025 |
| FY2023 | Dec 31, 2021 | 2 | Nov 18, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 24, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 3 | Mar 14, 2025 |
| FY2023 | Dec 31, 2021 | 2 | Nov 18, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 24, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 56.33M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 56.09M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 55.77M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | 55.56M | Nov 18, 2024 |
| FY2022 | Dec 31, 2021 | 55.32M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | 54.76M | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | 52.08M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | 43.92M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | 43.59M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | 33.84M | Feb 22, 2018 |